Why AI matters at this scale

Eli Lilly and Company is a global pharmaceutical leader headquartered in Indianapolis, with a history dating back to 1876. The company discovers, develops, and markets medicines in key therapeutic areas including diabetes, oncology, neuroscience, and immunology. With over 10,000 employees and annual revenue exceeding $38 billion, Lilly operates at a scale where incremental efficiencies in R&D and operations translate to billions in value and, more importantly, can accelerate life-saving treatments to patients.

For an enterprise of Lilly's magnitude in the highly regulated pharmaceutical sector, AI is not merely a tool for optimization—it is a transformative lever for core business survival. The traditional drug development model is notoriously costly and slow, often exceeding $2 billion and 10 years per approved therapy. AI presents a paradigm shift, offering the potential to de-risk R&D investments, personalize medicine, and streamline global operations. At this size, the company has the capital, data assets, and strategic imperative to make foundational AI investments that smaller players cannot, positioning it to redefine industry benchmarks for innovation speed and efficiency.

Concrete AI Opportunities with ROI Framing

1. Accelerating Drug Discovery & Development: Generative AI models can design novel molecular structures with desired properties, while predictive AI can simulate clinical outcomes. This can reduce the pre-clinical research phase by years, potentially saving hundreds of millions in early-stage costs and creating a pipeline advantage worth billions in future revenue.

2. Optimizing Global Clinical Trials: AI algorithms can mine electronic health records to identify ideal trial participants faster, predict patient adherence issues, and enable decentralized trial monitoring through digital biomarkers. This can cut patient recruitment time by 30-50% and reduce trial costs significantly, improving the return on the ~$9 billion annual R&D spend.

3. Enhancing Manufacturing & Supply Chain Resilience: In large-scale pharmaceutical manufacturing, AI-driven predictive maintenance can prevent costly downtime in sterile production environments. AI can also optimize complex global supply chains for raw materials and finished goods, ensuring continuity and reducing waste, directly protecting multi-billion-dollar product revenue streams.

Deployment Risks Specific to This Size Band

For a 10001+ employee global corporation, AI deployment faces unique hurdles. Integration Complexity is paramount, as AI systems must connect with decades-old legacy ERP, clinical, and manufacturing systems across continents. Data Silos are exacerbated by size; unifying data from R&D, clinical operations, and commercial functions for AI consumption is a massive governance challenge. Organizational Inertia can slow adoption; shifting the mindset of thousands of employees and securing buy-in from numerous executive stakeholders requires concerted change management. Finally, the Regulatory Scrutiny is intense; any AI used in drug discovery or clinical decision-making must undergo rigorous validation by global health authorities like the FDA, adding time and cost to implementation. Navigating these risks requires a centralized AI strategy with strong executive sponsorship, dedicated cross-functional teams, and a phased, use-case-driven approach to prove value and build institutional confidence.